Merck & Company Inc (MRK)vsInsulet Corporation (PODD)
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
PODD
Insulet Corporation
$170.62
+1.88%
HEALTHCARE · Cap: $11.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2167% more annual revenue ($65.77B vs $2.90B). MRK leads profitability with a 13.6% profit margin vs 10.4%. PODD appears more attractively valued with a PEG of 1.45. PODD earns a higher WallStSmart Score of 73/100 (B).
MRK
Hold50
out of 100
Grade: D+
PODD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 33.9% year-over-year
Earnings expanding 159.0% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 9.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth, EPS Growth, Return on Equity. Revenue growth of 33.9% demonstrates continued momentum. PEG of 1.45 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio, Price/Book.
Key Dynamics to Monitor
MRK profiles as a value stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.11 — expect wider price swings.
PODD is growing revenue faster at 33.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (73/100 vs 50/100) and 33.9% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?